Report cover image

Next-Generation Breast Cancer Diagnostic & Screening Market by Product (Accessories, Breast Imaging Systems, Software & Services), Diagnostic Technology (DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics), Screening Technol

Publisher 360iResearch
Published Apr 17, 2024
Length 197 Pages
SKU # IRE18713396

Description

Next-Generation Breast Cancer Diagnostic & Screening Market by Product (Accessories, Breast Imaging Systems, Software & Services), Diagnostic Technology (DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics), Screening Technology, Application, End User - Global Forecast 2024-2030


The Next-Generation Breast Cancer Diagnostic & Screening Market size was estimated at USD 22.81 billion in 2023 and expected to reach USD 25.12 billion in 2024, at a CAGR 10.91% to reach USD 47.11 billion by 2030.

Next-generation breast cancer diagnostic & screening technologies represent a paradigm shift in how breast cancer is detected and diagnosed, offering more precise, efficient, and less invasive methods compared to traditional modalities. These advanced technologies, including digital mammography, 3D mammography (tomosynthesis), automated breast ultrasound, and molecular breast imaging, leverage high-end imaging and genomic profiling to identify breast cancers at an early stage when they are most treatable. Major factors driving the adoption of these novel diagnostic tools include the prevalence of breast cancer globally, increased awareness and advocacy for early detection, advancements in imaging technology, and a push toward personalized medicine. Despite their significant importance, these next-generation technologies face utility challenges such as high costs, limited access in low-resource settings, and the potential for overdiagnosis leading to unnecessary treatments. Addressing these restraints requires concerted efforts to reduce costs through technological innovations and scale, improving healthcare infrastructure, and implementing more nuanced screening protocols to balance early detection with the risk of overdiagnosis. Integration of artificial intelligence to improve diagnostic accuracy, the development of portable screening devices to increase access, and the continuous evolution of genomic profiling to predict breast cancer risk and tailor screening strategies accordingly are expected to expand the next-generation breast cancer diagnostic & screening space in the coming years.



Please Note: PDF & Excel + Online Access - 1 Year

Table of Contents

197 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of breast cancer worldwide
5.1.1.2. Growing inclination towards early diagnosis and treatment of diseases
5.1.1.3. Government initiatives to raise awareness regarding breast cancer
5.1.2. Restraints
5.1.2.1. Expensive breast cancer diagnostic & screening technologies
5.1.3. Opportunities
5.1.3.1. Advancements in next-generation breast cancer diagnostic & screening technologies
5.1.3.2. Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
5.1.4. Challenges
5.1.4.1. Complexity in manufacturing and stringent regulatory approval process
5.2. Market Segmentation Analysis
5.2.1. Product: Need for advanced breast imaging systems for enhanced clinical outcomes
5.2.2. End User: Expanding use of breast cancer diagnostics in hospitals to cater to a wider patient population
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Next-Generation Breast Cancer Diagnostic & Screening Market, by Product
6.1. Introduction
6.2. Accessories
6.3. Breast Imaging Systems
6.4. Software & Services
7. Next-Generation Breast Cancer Diagnostic & Screening Market, by Diagnostic Technology
7.1. Introduction
7.2. DNA Microarrays
7.3. Lab-on-a-Chip & Reverse Transcriptase-PCR
7.4. Molecular Diagnostics
7.5. Next Generation Sequencing
7.6. Protein Microarrays
7.7. qPCR & Multiplexing
8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Screening Technology
8.1. Introduction
8.2. Ionizing Breast Imaging Technologies
8.3. Non-ionizing Breast Imaging Technologies
9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application
9.1. Introduction
9.2. Cancer Screening
9.3. Companion Diagnostics
9.4. Risk Analysis
9.5. Therapeutic Monitoring
10. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User
10.1. Introduction
10.2. Breast Care Centers
10.3. Diagnostic Imaging Centers
10.4. Hospitals & Clinics
11. Americas Next-Generation Breast Cancer Diagnostic & Screening Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Next-Generation Breast Cancer Diagnostic & Screening Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Next-Generation Breast Cancer Diagnostic & Screening Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection
14.3.2. Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
14.3.3. Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets
14.4. Strategy Analysis & Recommendation
15. Competitive Portfolio
15.1. Key Company Profiles
15.2. Key Product Portfolio
FIGURE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET RESEARCH PROCESS
FIGURE 2. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET DYNAMICS
FIGURE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
FIGURE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2023 VS 2030 (%)
FIGURE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 20. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 26. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us